Just before the new year, U.S. Surgeon General Jerome Adams recommended to legally reclassify cannabis out of Schedule 1 substance. The Surgeon General made the recommendation for reclassification in order to reduce complications behind medical research on cannabis.
A change to the classification of cannabis to a lesser schedule would bring significant reform to the justice system, an economic boom for the U.S., and, of course, easier access with medical research and studies. The cannabis plant contains hundreds of chemicals with potential medical benefit like the Food and Drug Administration (FDA) approved cannabidiol (CBD) oil. CBD, which is non-psychoactive, has been FDA approved to treat a wide range from anxiety to epilepsy.
Surgeon General Jerome Adams’ opinion on cannabis hasn’t changed since shortly after he first took office in September of 2017. “Under medical marijuana, I believe it should be like any other drug. We need to let the FDA vet it, study it, vet it. The FDA has actually approved cannabidiol oil and some derivatives of marijuana, Marijuana is not one substance,” Adams said in 2017.
Chief Executive Officer of ANANDA, Dr. Mark Rosenfeld, stated: “The relevance of the Surgeon General’s call to reschedule cannabis cannot be understated,” says Dr. Mark Rosenfeld, CEO of ANANDA Scientific.”
The Surgeon’s General comments on cannabis reclassification come shortly after a congressional report titled, “The National Cannabis Economy” was released. This report contained a highlight that this year’s cannabis sales alone will be more than $11 billion. By 2022 it is estimated that cannabis sales will reach $23 billion from “job creation, more tax revenue, and better patient care”.
Want to learn about other great cannabis legalization news? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.